OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Cancers & treatments·Sequencing

IDH1- and IDH2-mutated acute myeloid leukaemia: lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineFitFRαIDH
Advanced, first line1··
Third line and beyond·1·
Special situations··1

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
FitNewly diagnosed, fit for intensive chemotherapy7+3 induction with consolidation and transplant by ELN risk; IDH inhibitors added in trials.
Cytarabine + anthracycline ('7+3')Allogeneic stem cell transplantationIvosidenib
92

Third line and beyond

SubgroupSettingApproachProducts and trialsEvidence
FRαRelapsed or refractoryIvosidenib or olutasidenib for IDH1, enasidenib for IDH2; venetoclax-based combinations; transplant in responders.
IvosidenibOlutasidenibEnasidenibVenetoclaxAllogeneic stem cell transplantation
92

Special situations

SubgroupSettingApproachProducts and trialsEvidence
IDHNewly diagnosed IDH1-mutated, unfit for intensive chemotherapyIvosidenib plus azacitidine (AGILE) or venetoclax plus azacitidine; triplets in trials.
IvosidenibAzacitidineAGILEVenetoclaxVIALE-A
93

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.